Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 6/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4614191 | 0.99 | HTR1A (0.43) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL4616259 | 0.93 | HTR6 (0.45) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| Hydrochloric Acid SCHEMBL4616001 | 0.92 | HTR6 (0.44) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL4615517 | 0.84 | HTR6 (0.41) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| Hydrochloric Acid SCHEMBL4668606 | 0.83 | HTR6 (0.41) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL4614996 | 0.82 | HTR6 (0.51) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL4615350 | 0.82 | HTR6 (0.46) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| Hydrochloric Acid SCHEMBL4614811 | 0.81 | HTR6 (0.50) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| Hydrochloric Acid SCHEMBL4613661 | 0.81 | HTR6 (0.45) | HTR1ASLC6A2SLC6A4HTR6DRD2 | |
| SCHEMBL3854910 | 0.80 | HTR1A (0.49) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708713-B1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | claimed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | claimed |
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | claimed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | claimed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1708713-B1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | HTR1A 731/4885SLC6A2 1342/4885SLC6A4 1037/4885 |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | HTR1A 731/4885SLC6A2 1342/4885SLC6A4 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.